CDK2 and cancer: One study examining CDK dependencies in RB-proficient cancer cell types identified a subset of cell lines that relied on Cyclin E–CDK2 complexes for RB phosphorylation, independent of CDK4/6 activity, as evidenced by their resistance to cell cycle arrest from targeted deletions of CDK4 and CDK6 [64].